XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Equity
 9 Months Ended
Nov. 02, 2024
Equity [Abstract]  
Equity Equity
As of November 2, 2024, there were 268,848,415, 292,349,200, and no shares of Class A, Class B, and Class C common stock issued and outstanding, respectively. As of February 3, 2024, there were 200,989,931, 344,983,598, and no shares of Class A, Class B, and Class C common stock issued and outstanding, respectively.
The Company had reserved shares of common stock for future issuance as of November 2, 2024 and February 3, 2024, as follows:
As of
November 2, 2024February 3, 2024
2015 Equity Incentive Plan:
Options outstanding5,635,770 6,165,885 
RSUs outstanding1,727,814 6,654,559 
2021 Equity Incentive Plan:
RSUs outstanding25,121,928 28,716,715 
Shares available for future grants90,063,448 68,321,018 
2021 Employee Stock Purchase Plan:
Shares available for future issuance21,719,508 16,875,966 
Total shares of common stock reserved for future issuance144,268,468 126,734,143 
Employee Compensation Plans
The Company currently has two equity incentive plans, the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2021 Equity Incentive Plan (the “2021 Plan”). The 2015 Plan was terminated in connection with the adoption of the 2021 Plan in December 2021 but continues to govern the terms of outstanding stock options and RSUs that were granted prior to the termination of the 2015 Plan. The Company no longer grants equity awards pursuant to the 2015 Plan.
2021 Equity Incentive Plan—In December 2021, the Board of Directors adopted and stockholders approved the 2021 Plan, which became effective in December 2021 in connection with the Company’s initial public offering (“IPO”). The total number of shares of the Company’s Class A common stock reserved for future grants as of November 2, 2024 includes 27,298,676 shares added on the first day of fiscal year 2025 pursuant to the annual automatic evergreen increase provision of the 2021 Plan.
Options—A summary of the stock options activity under the 2015 Plan during the nine months ended November 2, 2024 is presented below (the number of options represents shares of common stock exercisable in respect thereof):
Number of SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining
Contractual Term
(In Years)
Aggregate Intrinsic Value (1)
(In Thousands)
Balance as of February 3, 20246,165,885 $5.07 5.7$169,153 
Granted— $— 
Exercised(530,115)$1.62 
Forfeited, canceled, or expired— $— 
Balance as of November 2, 20245,635,770 $5.40 5.1$230,043 
Exercisable as of November 2, 20245,635,770 $5.40 5.1$230,043 
__________
(1)Aggregate intrinsic value for stock options represents the difference between the exercise price and the per share fair value of the Company’s Class A common stock for each period end presented, multiplied by the number of stock options outstanding or exercisable as of each period end presented.
The intrinsic value of stock options exercised was $21.0 million and $11.7 million during the nine months ended November 2, 2024 and October 28, 2023, respectively.
As of November 2, 2024, the Company had no remaining unrecognized stock-based compensation expense related to outstanding unvested stock options for employees that are expected to vest.
RSUs—RSUs granted prior to the IPO had both a service condition and a performance condition (defined under the 2015 Plan as the occurrence of a qualifying liquidity event, which was defined as the earlier of a successful IPO or acquisition). Stock-based compensation expense was only recognized for RSUs for which both the service condition and performance condition have been met. The service condition for these awards is generally satisfied over four years. The performance condition was satisfied upon the IPO. Prior to the IPO, the Company did not record expense on RSUs as a liquidity event upon which vesting is contingent was not probable of occurring. Following the closing of the IPO in December 2021, the Company began recording stock-based compensation expense for these RSUs using the accelerated attribution method, based on the grant-date fair value of the RSUs. RSUs granted after the IPO only have a service condition, and the related stock-based compensation expense is recognized on a straight-line basis over the requisite service period. The service condition for these awards is generally satisfied over four years for RSUs granted through fiscal year 2023 and either three or four years for RSUs granted after fiscal year 2023.
A summary of the RSUs activity under the 2015 Plan and 2021 Plan during the nine months ended November 2, 2024 is presented below:
Number of SharesWeighted-Average
Grant-Date
Fair Value
Balance as of February 3, 202435,371,274 $15.17 
Granted10,217,066 $34.81 
Vested(14,077,918)$16.36 
Forfeited(4,660,680)$16.93 
Balance as of November 2, 202426,849,742 $21.72 
As of November 2, 2024, unrecognized stock-based compensation expense related to outstanding unvested RSUs for employees that are expected to vest was approximately $532.6 million. The remaining unrecognized stock-based compensation expense is expected to be recognized over a weighted-average period of approximately 1.3 years.
2021 Employee Stock Purchase Plan—In December 2021, the Board of Directors adopted and stockholders approved the 2021 Employee Stock Purchase Plan (the “2021 ESPP”), which became effective in December 2021 in connection with the IPO. The total number of shares of the Company’s Class A common stock reserved for future issuance as of November 2, 2024 includes 5,459,735 shares added on the first day of fiscal year 2025 pursuant to the annual automatic evergreen increase provision of the 2021 ESPP.
The price at which Class A common stock is purchased under the 2021 ESPP is equal to 85% of the lower of the fair market value of a share of the Company’s Class A common stock on the enrollment date or on the exercise date. The enrollment date means the first trading day of each offering period, and the exercise date means the last trading day of each purchase period. Offering periods are generally 12 months long, commencing on the first trading day on or after June 11 and December 11 of each year and terminating on the last trading day on or before June 10 and December 10 of each year. Purchase periods are generally six months long, commencing on the first trading day after one exercise date and ending with the next exercise date.
For the nine months ended November 2, 2024 and October 28, 2023, 616,193 and 1,152,816 shares of Class A common stock were purchased under the 2021 ESPP, resulting in net cash proceeds of $16.1 million and $13.0 million, respectively.
As of November 2, 2024, unrecognized stock-based compensation expense related to the 2021 ESPP was approximately $3.6 million. The remaining unrecognized stock-based compensation expense is expected to be recognized over a weighted-average period of approximately 0.5 years.
Employee Stock Purchase Plan Valuation—The Company estimates the fair value of shares to be issued under the 2021 ESPP using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which greatly affect fair value. The weighted-average assumptions used to estimate the fair value of shares to be issued under the 2021 ESPP were as follows:
Nine Months Ended
November 2, 2024October 28, 2023
Expected volatility
53.2% – 57.4%
66.9% – 72.5%
Expected term (years)
0.5 – 1.0
0.5 – 1.0
Risk-free interest rate
5.2% – 5.4%
5.2% – 5.4%
Expected dividend yield—%—%
Expected volatility—The expected volatility for the nine months ended November 2, 2024 and October 28, 2023 was based on the historical volatility of the Company.
Expected term (years)—The expected term is approximately 0.5 years for the first purchase period and approximately 1.0 year for the second purchase period.
Risk-free interest rate—The risk-free interest rate assumption is based on observed U.S. Treasury yield curve interest rates in effect at the time of grant appropriate for the expected term of the stock-based award.
Expected dividend yield—Because the Company has never paid and has no current intention to pay cash dividends on its common stock, the expected dividend yield is zero.
Stock-Based Compensation Expense—Stock-based compensation expense, by grant type, was as follows (in thousands):
Three Months EndedNine Months Ended
November 2, 2024October 28, 2023November 2, 2024October 28, 2023
Stock options$612 $771 $2,169 $2,357 
RSUs68,895 55,165 197,393 160,255 
Employee stock purchase plan3,085 3,855 9,290 9,783 
Total stock-based compensation expense$72,592 $59,791 $208,852 $172,395 
Stock-based compensation expense included in the following line items of the Company’s condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
Three Months EndedNine Months Ended
November 2, 2024October 28, 2023November 2, 2024October 28, 2023
Cost of revenue$3,041 $2,936 $9,189 $8,698 
Research and development26,899 21,523 76,275 64,378 
Sales and marketing22,008 19,253 61,886 51,832 
General and administrative20,644 16,079 61,502 47,487 
Total stock-based compensation expense$72,592 $59,791 $208,852 $172,395